Table 2. Costs, utilities, and discount rates of the USA and China in the model.
| Parameter | The United States | China | |||||
|---|---|---|---|---|---|---|---|
| Value (range) | Distribution | Reference | Value (range) | Distribution | Reference | ||
| Costs per cycle (US $) | |||||||
| Dacomitinib | 7,385 (5,539–9,231) | Gamma | Red Book | 1,731 (865*–2,163) | Gamma | Local charge | |
| Gefitinib | 6,218 (4,664–7,773) | Gamma | Red Book | 163 [122–204] | Gamma | (27) | |
| ADR of Dac. | 3.23 (2.42–4.04) | Gamma | (9,28,29), OCC | 1.88 (1.41–2.35) | Gamma | (9), local charge | |
| ADR of Gef. | 0.35 (0.26–0.44) | Gamma | (9,28-31), OCC | 3.38 (2.54–4.23) | Gamma | (9), local charge | |
| Follow-up | 437 [328–546] | Gamma | (32) | 269 [201–336] | Gamma | Local charge | |
| PD therapy | 12,636 (9,477–15,795) | Gamma | (33) | 28,644 (21,483–35,805) | Gamma | (34-36) | |
| Utility | |||||||
| PFS | 0.84 (0.71–0.966) | Beta | (25,26) | 0.804 (0.683–0.925) | Beta | (25,26) | |
| PD | 0.166 (0.14–0.19) | Beta | (25,26) | 0.321 (0.273–0.369) | Beta | (25,26) | |
| Discount rate per year (%) | |||||||
| Cost | 3 (0–6) | – | (12) | 5 (0–8) | – | (12) | |
| Outcome | 3 (0–6) | – | (12) | 5 (0–8) | – | (12) | |
*, in China, due to the price negotiation between China’s National Healthcare Security Administration (NHSA) and pharmaceutical companies, the dacomitinib range was set to 50–125%. OCC, outpatient care center; ADR, adverse drug reaction; PD, progressive disease; PFS, progression-free survival; OS, overall survival.